Completed PHASE2 INTERVENTIONAL 2-arm NCT05262218

Therapeutic Effect of PBF-680 in Patients With COPD (Respire)

A Phase IIa, Randomized, Double Blind, Placebo Controlled Study to Assess the Effect of PBF-680 in Patients With Moderate to Severe COPD on Top of the Standard Medication

Sponsor: Palobiofarma SL

Conditions COPD

Interventions PBF-680 10mg Placebo

Updated 6 times since 2022 Last updated: Apr 18, 2024 Started: Dec 20, 2021 Primary completion: Feb 27, 2024 Completion: Apr 9, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05262218, this PHASE2 trial focuses on COPD and remains completed. Sponsored by Palobiofarma SL, it has been updated 6 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
May 2024 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Mar 2024 — May 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2023 — Mar 2024 [monthly]

Recruiting PHASE2

▶ Show 1 earlier version

Apr 2022 — Feb 2023 [monthly]

Recruiting PHASE2

First recorded

Dec 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Palobiofarma SL
Scope International AG

Data source: Palobiofarma SL

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Barcelona, Spain
• Pamplona, Spain